+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-10-18Number of Pages: 173

Plasma Protease C1-inhibitor Treatment Market (Drug Class- C1-inhibitors (C1-esterase Inhibitor and Recombinant Inhibitor), Kallikrein Inhibitor (Kalbitor), and Selective Bradykinin B2 Receptor Antagonist (Firazyr); Distribution Channel - Hospital Pharmacies and Independent Pharmacies and Outlets; Dosage Type - Lyophilized and Liquid/Injectable) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Global Plasma Protease C1-inhibitor Treatment Market: Snapshot

The global plasma protease C1-inhibitor treatment market is foreseen to display robust growth in the future due to the increasing cases of acute hereditary angioedema (HAE) and prophylaxis. The emergence of a few drug variants of C1-inhibitor is considered to be a major breakthrough for patients suffering from HAE that are administered either intravenously or subcutaneously.

According to a report by Transparency Market Research (TMR), the global plasma protease C1-inhibitor treatment market was evaluated at US$1.5 bn in 2016. The report forecasts the demand in the global plasma protease C1-inhibitor market will rise at a robust 20.0% CAGR for the forecast period of 2017 to 2025, for the market to be valued at US$7.9 bn by the end of 2025.

plasma protease c1 inhibitor treatment market

 

Extensive Use for HAE Makes C1-inhibitor Drug Class Dominant

Based on drug class, the global plasma protease C1-inhibitor market is classified into C1-inhibitor, Kallikrein inhibitor, and selective Bradykinin B2 receptor antagonist (Firazyr). The C1-inhibitor segment held the leading market share in 2016 as these drugs are widely used for the treatment of acute HAE and prophylaxis. The segment of Selective Bradykining B2 Receptor is anticipated to display the leading growth rate over the forecast period. This is mainly because of expanding R&D activities that key players are engaged in for the development of new C1-inhibitor deficiency drugs that can be administered subcutaneously. On the other hand, the segment of Kallikrein inhibitor (Kalbitor) is predicted to register a moderate CAGR between 2017 and 2025. The growth of Kallikrein inhibitor segment is attributable to the rising preference for self-administrable drugs. Moreover, the rising preference for Firazyr is anticipated to hamper the growth of Kalbitor segment. However, increasing approval of Kallikrein drugs and positive results obtained for pre-clinical treatment of HAE cases are likely to augment the growth rate of this segment moderately over the forecast period.

On the basis of dosage type, the market is segregated into lyophilized and liquid/injectable. Of the two, lyophilized segment held the leading market share in 2016 on the back of increasing practice of intravenous administration of drugs for the treatment of HAE. Further, rising demand for intravenous C1 esterase inhibitor drugs in emerging markets of Asia Pacific and Latin America is anticipated to positively influence the lyophilized segment.

However, the liquid/injectable segment is likely to hold significant market share by 2025 due to several factors. This includes rising demand for subcutaneous administration of drugs, less adverse effects, cost effectiveness, and increased preference for Firazyr over Kalbitor by physicians. The expected launch of subcutaneous Cinryze, Berinert, and DX-2930 will further hamper the growth of lyophilized segment. To stay competitive, companies are vying to introduce the subcutaneous variants of Cinryze and Berinet for prophylactic treatment and are expected to be commercially available by 2019 and 2018 respectively. Despite the liquid/injectable nature of Firazyr and Kalbitor the side-effects associated with them can hamper the liquid/injectable segment over the forecast period.

In terms of distribution channel, the market has been bifurcated into hospital pharmacies and independent pharmacies & outlets in this report. Of the two, independent pharmacies & outlets dominated the market in 2016; the segment is anticipated to hold dominance through 2025.

North America to Lead Plasma Protease C1-inhibitor Treatment Market through 2025

Geographically, the plasma protease C1-inhibitor treatment market is divided into four key regions, namely North America, Europe, Latin America, and Rest of the World. Among these, North America stood as the leading contributor to the worldwide market for plasma protease C1-inhibitor treatment market in 2016. High prevalence of HAE in the U.S. that are actually diagnosed and treated using C1-inhibitor drugs account for the leading growth of this regional market.

The global plasma protease C1-inhibitor treatment market features a highly consolidated vendor landscape. Shire plc, Pharming Group N.V., CSL Limited, and Sanquin are the key companies operating in this market.

Global Plasma Protease C1-inhibitor Treatment Market: Overview

This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.

The plasma protease C1-inhibitors treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, dosage type, distribution channel and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises Porters Five Forces analysis to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global plasma protease C1-inhibitors treatment market.

Global Plasma Protease C1-inhibitor Treatment Market: Market Segmentation

Based on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Based on distribution channel, the plasma protease C1-inhibitors treatment market has been segmented into four major categories: hospital pharmacies, and independent pharmacies & outlets. The plasma protease C1-inhibitors treatment market is also segmented into dosage type lyophilized and liquid/injectable. The market segments have been extensively analyzed based on prevalence of the diseases, available treatment, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Geographically, the global plasma protease C1-inhibitors treatment market has been categorized into four major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (EU-5 Countries, BENELUX Countries, and Rest of Europe), Latin America (Brazil, Argentina, and Rest of Latin America) and Rest of World (Australia, Israel, and Rest of World Countries). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Global Plasma Protease C1-inhibitor Treatment Market: Competitive Landscape

The report also profiles major players in the global plasma protease C1-inhibitors treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Shire plc, CSL Limited, Sanquin and Pharming Group N.V.

The Global Plasma Protease C1-inhibitor Treatment Market is segmented as given below:

  • Global Plasma Protease C1-inhibitors Treatment Market, by Drug Class 
    • C1-inhibitors
      • C1-esterase Inhibitor
      • Recombinant Inhibitor
    • Kallikrein Inhibitor (Kalbitor)
    • Selective Bradykinin B2 Receptor Antagonist (Firazyr)
       
  • Global Plasma Protease C1-inhibitors Treatment Market, by Dosage Type
    • Liquid/Injectable
    • Lyophilized
       
  • Global Plasma Protease C1-inhibitors Treatment Market, by Distribution Channel
    • Hospital Pharmacies
    • Independent Pharmacies and Outlets
       
  • Global Plasma Protease C1-inhibitors Treatment Market, By Geography
    • North America
      • U.S.
      • Canada
    • Europe
      • EU-5 Countries
      • BENELUX Countries
      • Rest of Europe
    • Latin America
      • Argentina
      • Brazil
      • Rest of Latin America
    • Rest of World
      • Australia
      • Israel
    • Rest of World Countries


 
 
Back To Top